Company intelligence / Profile preview

NoveCite

Cranford, New Jersey, United States

Ownership: Public · CTXR
Development stage: Other

Overview

Preclinical results in large animal models of ARDS show improvement in clinical parameters (oxygenation, reduced systemic shock, and lung injury) compared to controls. The iMSC product demonstrated superior potency, viability, and high secretion of immunomodulatory proteins that may help reduce pulmonary symptoms associated with ARDS; further regulatory interaction (pre-IND meeting with FDA) has occurred.

Therapeutic areas: Infectious DiseasesPulmonology
Modalities: Induced pluripotent stem cell derived therapyCell therapyMesenchymal stem cell therapyBiologic
Industry: Biotech

Partnerships

Novellus Therapeutics (exclusive worldwide license for iMSC technology/platform)

Beyond the preview

Go deeper on NoveCite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NoveCite.